Alluvi, previously BI 4744, offers a notable breakthrough in obesity therapy. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates compelling efficacy in research assessments, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/